A six-month study found that henagliflozin may help reduce harmful heart changes in people with type 2 diabetes and high blood pressure.
4 min read · Published 2026-07-13
This is a plain-language summary, written by Celio Health, of a study published in Cardiovascular Diabetology (2026-07-11). Read the original: Henagliflozin attenuates adverse ventricular remodeling and improves cardiometabolic parameters in patients with type 2 diabetes and hypertension: real-world evidence from a propensity score-matched analysis (PMID 42436477).
Researchers in China conducted a real-world study published in Cardiovascular Diabetology to see how a medication called henagliflozin affects the heart in people living with both type 2 diabetes and hypertension. They followed 132 patients over six months—66 taking henagliflozin along with their regular medications, and 66 taking standard therapy alone. The main focus was whether henagliflozin could reduce the thickness of the left ventricle (the heart's main pumping chamber), which tends to enlarge and thicken when blood sugar and blood pressure stay too high for too long.
After six months, patients on henagliflozin showed a decrease in left ventricular thickness, while those on standard therapy alone saw an increase. The henagliflozin group also had improvements in how the heart filled with blood and in the size of the heart's upper chamber. Additionally, the left ventricular pumping ability improved slightly in the treatment group. These findings suggest the medication may help prevent or reverse some of the harmful structural changes that occur when diabetes and high blood pressure persist.
Beyond heart structure, the henagliflozin group experienced better control of blood sugar and lower blood pressure compared to the control group. Fasting glucose levels dropped more, and hemoglobin A1c—a marker of average blood sugar over three months that a clinician might discuss with patients—showed greater improvement. Systolic and diastolic blood pressure both fell more significantly in the henagliflozin group, and patients also lost a bit more weight on average.
These cardiometabolic improvements happened in addition to the heart-structure changes, suggesting the drug may work through multiple pathways to benefit people with these overlapping conditions.
When diabetes and hypertension occur together, the heart often thickens as it works harder to pump against high pressure. This thickening, called left ventricular hypertrophy, increases the risk of heart failure and other complications. A medication that can slow or reverse this process—while also improving blood sugar and blood pressure—could provide meaningful protection. However, this was a single-center study of moderate size, so findings would benefit from confirmation in larger, longer-term trials.
This study was observational and lasted only six months, so longer-term effects remain unknown. Although the researchers used propensity score matching to make the two groups more similar, some unmeasured differences between patients could have influenced the results. The study was also conducted at one hospital in China, so results may not apply equally to all populations. Additionally, henagliflozin is not yet approved in all countries, and anyone considering this or any medication should discuss risks and benefits with their doctor.
A six-month study suggests henagliflozin may help reduce harmful heart thickening in people with type 2 diabetes and high blood pressure, while also improving blood sugar control. Larger, longer-term studies are needed to confirm these findings and understand their real-world impact. Anyone interested in this medication should speak with their healthcare provider about whether it's appropriate for their specific situation.
This summary is for general education, is not medical advice, and does not diagnose or treat any condition. Studies like this describe what researchers observed, not a recommendation for you. Talk with a qualified clinician about your health, and read how we write about research in our editorial policy.
This research touches on markers a clinician might discuss. Learn what they measure, or order a physician-reviewed test — no appointment needed.
Markers mentioned: